• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Seer Inc Cl A (NQ: SEER )

    2.030 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Seer Inc Cl A

    < Previous 1 2 3 4 5 Next >
    Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer’s, Lung Cancer, and More at ASHG 2024
    CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer’s Proteograph™ Product Suite 
    From Seer, Inc.
    Via GlobeNewswire
    Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer’s, Population Health, and Xenotransplantation at HUPO 2024
    Seer’s Proteograph™ Product Suite reveals new insights into Alzheimer’s pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional... 
    From Seer, Inc.
    Via GlobeNewswire
    Recap: Seer Q4 Earnings
    Via Benzinga
    Earnings Scheduled For February 29, 2024
    Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
    Via Benzinga
    Seer to Report Third Quarter 2024 Financial Results on November 6, 2024
    From Seer, Inc.
    Via GlobeNewswire
    Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
    From Seer, Inc.
    Via GlobeNewswire
    Seer Appoints Nicolas Roelofs to its Board of Directors
    From Seer, Inc.
    Via GlobeNewswire
    Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference
    From Seer, Inc.
    Via GlobeNewswire
    SEER Stock Earnings: Seer Beats EPS, Misses Revenue for Q2 2024
    SEER stock results show that Seer beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Seer Reports Second Quarter 2024 Financial Results
    Launched STAC in Europe and additional customer papers published in leading journals 
    From Seer, Inc.
    Via GlobeNewswire
    Seer to Report Second Quarter 2024 Financial Results on August 8, 2024
    From Seer, Inc.
    Via GlobeNewswire
    Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
    From Seer, Inc.
    Via GlobeNewswire
    Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
    Combined Workflow of Proteograph™ XT Assay and Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer Robustly Identifies over 13,000 Protein Groups Across a Study of 2,840 Subjects 
    From Seer, Inc.
    Via GlobeNewswire
    SEER Stock Earnings: Seer Meets EPS, Misses Revenue for Q1 2024
    SEER stock results show that Seer met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Seer Reports First Quarter 2024 Financial Results
    Demonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publications 
    From Seer, Inc.
    Via GlobeNewswire
    Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions
    From Seer, Inc.
    Via GlobeNewswire
    Seer to Report First Quarter 2024 Financial Results on May 8, 2024
    From Seer, Inc.
    Via GlobeNewswire
    Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
    Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data 
    From Seer, Inc.
    Via GlobeNewswire
    Seer to Participate in the TD Cowen 44th Annual Health Care Conference
    From Seer, Inc.
    Via GlobeNewswire
    Zoom Video And 2 Other Stocks Insiders Are Selling
    The Nasdaq 100 closed higher by around 1% on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
    Via Benzinga
    Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery
    From Seer, Inc.
    Via GlobeNewswire
    Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
    From Seer, Inc.
    Via GlobeNewswire
    Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference
    From Seer, Inc.
    Via GlobeNewswire
    Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum
    From Seer, Inc.
    Via GlobeNewswire
    Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500
    Seer technology receives recognition for excellence in the field of proteomics 
    From Seer, Inc.
    Via GlobeNewswire
    Seer Reports Third Quarter 2023 Financial Results
    Expanded access to the Proteograph™ Product Suite through the Seer Technology Access Center, new distributors and a new Center of Excellence 
    From Seer, Inc.
    Via GlobeNewswire
    Earnings Scheduled For November 7, 2023
    Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
    Via Benzinga
    Seer Announces Addition of Panome Bio to Centers of Excellence (COE) Program
    Panome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services 
    From Seer, Inc.
    Via GlobeNewswire
    Seer to Report Third Quarter 2023 Financial Results on November 7, 2023
    From Seer, Inc.
    Via GlobeNewswire
    7 Contrarian Stocks to Buy for the High-Stakes Gambler
    With limited options available as the market rotates out of risk-on assets, speculators may try their luck with contrarian stocks to buy. 
    Via InvestorPlace
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.